Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an open-label safety and feasibility trial evaluating the use of paired non-invasive vagus nerve stimulation (VNS) and upper extremity (UE) rehabilitation in the motor impairment reduction of adolescent patients with spastic cerebral palsy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Non-invasive VNS | Experimental | Non-invasive, transauricular, vagus nerve stimulation device will be used during physical therapy rehabilitation sessions |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Non-invasive taVNS | Device | Device activates the vagus through the ear. The device is controlled via the Vagustim mobile app, which connects using Bluetooth Low Energy (BLE). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of adverse event and serious adverse events | Safety is assessed by adverse event. | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Number of therapy sessions complete | Number of therapy sessions complete | end of therapy visits at Day 46 |
| Active training time per session | Number of minutes of training per session |
Not provided
Inclusion criteria:
Exclusion criteria:
Previous vagus nerve injury
Less than 12 years old or greater than 18 years old
History of left or bilateral vagotomy
Current use of other implanted stimulation devices including but not limited to pacemaker, deep brain stimulator, implanted vagus nerve stimulators, cochlear implants, implantable cardiac defibrillators (ICDs)etc.
Current use of any investigational devices or investigational drugs not otherwise specified - Past Medical History for any of the following:
GMFCS score of less than II or greater than III (will be evaluated at screening)
Jebsen Taylor Hand Function Test Score of >37.08 on the affected side at time of screening visit (will be evaluated at screening)
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jenna Tosto Mancuso, PT, DPT,NCS | Contact | 212-241-8454 | jenna.tosto@mountsinai.org |
| Name | Affiliation | Role |
|---|---|---|
| David Putrino, PhD | Icahn School of Medicine at Mount Sinai | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Charles Lazarus Children's Abilities Center | Recruiting | New York | New York | 10029 | United States |
No: There is not a plan to make IPD available.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002547 | Cerebral Palsy |
| ID | Term |
|---|---|
| D001925 | Brain Damage, Chronic |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Open-label
Not provided
Not provided
Not provided
Not provided
|
| end of therapy visits at Day 46 |
| Number of movement repetitions completed per session | Number of movement repetitions completed per session. | end of therapy visits at Day 46 |
| Jebsen Taylor Hand Function Test (JTHFT) | The Jebsen Taylor Hand Function Test (JTHFT) is a standardized and objective measure of fine and gross motor hand functions that uses simulated activities of daily living (ADLs) assessed by time to completion; typically up to several minutes depending on impairment | baseline Day 1, start of therapy Day 3, end of therapy Day 46, and 3, 6, 9, and 12 months |
| BOT-2 | The BOT-2 is a standardized assessment of motor proficiency in children and adolescents. It evaluates fine motor skills, manual dexterity, coordination, and motor integration through structured performance tasks. Fine Motor Precision (Upper Extremity) scored 0-41, higher score indicates better precision Fine Motor Integration (Upper Extremity) scored 0-45, higher score indicates better integration Manual Dexterity (Upper Extremity) scored 0- 45, higher score indicates better manual dexterity. Upper-Limb Coordination scored 0-30, higher score indicates better upper-limb coordination. | baseline Day 1, start of therapy Day 3, end of therapy Day 46, and 3, 6, 9, and 12 months |
| ABILHANDS | ABILHAND is a patient-reported outcome measure that evaluates a person's perceived manual ability to perform daily bimanual activities. It assesses how difficult activities are to perform using both hands. The ABILHAND-Kids logit score ranges from -6 logits to +6 logits, higher score indicates better bimanual manual ability (tasks are perceived as easier). | baseline Day 1, start of therapy Day 3, end of therapy Day 46, and 3, 6, 9, and 12 months |
| Pediatric Evaluation of Disability (PEDI) | The PEDI assesses functional abilities and performance in children across three domains: self-care, mobility, and social function. It measures both capability and caregiver assistance. Subscale range and full range uses scaled scores standardized to a 0-100 metric. Higher scores indicate better functional abilities and greater independence. | at 12 months |
| Pediatric Quality of Life Inventory (PedsQL) | The PedsQL is a standardized patient-reported outcome measure assessing health-related quality of life in children across domains including physical, emotional, social, and school functioning. Subscales range and full scale scores are transformed to a 0-100 scale. Higher scores indicate better health-related quality of life. | baseline Day 1, start of therapy Day 3, end of therapy Day 46, and 3, 6, 9, and 12 months |